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Abstract
Cancer cells go through a process known as epithelial–mesenchymal transition (EMT) during which they acquire the
ability to migrate and invade extracellular matrix. Some cells also acquire the ability to move across a layer of
endothelial cells to enter and exit the bloodstream; intra- and extravasation, respectively. The transcription factor PRH/
HHEX (proline-rich homeodomain/haematopoietically expressed homeobox) controls cell proliferation and cell
migration/invasion in a range of cell types. Our previous work showed that PRH activity is downregulated in prostate
cancer cells owing to increased inhibitory PRH phosphorylation and that this increases cell proliferation and invasion.
PRH inhibits migration and invasion by prostate and breast epithelial cells in part by activating the transcription of
Endoglin, a transforming growth factor β (TGFβ) co-receptor. Here we show that depletion of PRH in immortalised
prostate epithelial cells results in increased extravasation in vitro. We show that blood platelets stimulate extravasation
of cells with depleted PRH and that inhibition of TGFβ signalling blocks the effects of platelets on these cells.
Moreover, TGFβ induces changes characteristic of EMT including decreased E-Cadherin expression and increased Snail
expression. We show that in prostate cells PRH regulates multiple genes involved in EMT and TGFβ signalling.
However, both platelets and TGFβ increase PRH phosphorylation. In addition, TGFβ increases binding of its effector
pSMAD3 to the PRH/HHEX promoter and downregulates PRH protein and mRNA levels. Thus, TGFβ signalling
downregulates PRH activity by multiple mechanisms and induces an EMT that facilitates extravasation and sensitises
cells to TGFβ.
Introduction
During metastasis, cancer cells undergo a change in
phenotype known as epithelial–mesenchymal transition
(EMT). In this process, the cancer cells lose normal
cell–cell interactions and apico-basal polarity and they
become migratory and invasive (reviewed by Shibue and
Weinberg 20171). This enables cancer cells to migrate
away from their site of origin, and it facilitates intrava-
sation, passage of cells across the endothelial cell barrier
and into a blood vessel and extravasation, passage from a
blood vessel into tissues. Once in their new location, the
reverse mesenchymal–epithelial transition is thought to
take place enabling the formation of secondary tumours.
EMT in cancer cells can also alter the behaviour of sur-
rounding cells that have not undergone EMT and alter the
response of cancer cells to chemotherapy2,3. Multiple
signalling molecules are known or suspected to be
important in the induction of EMT in pre-cancer cells in
the tumour microenvironment or in the maintenance of
the mesenchymal state in blood vessels, including factors
released by immune cells4,5.
Inﬂammation has a role in prostate tumourigenesis
through several mechanisms, including the creation of a
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tissue microenvironment capable of inducing cell repli-
cation, and the induction of neo-angiogenesis6. Multiple
cytokines have been identiﬁed as potential mediators
between prostatic inﬂammation and prostate cancer risk
and aggressiveness including IL-6, IL-2 and transforming
growth factor β (TGFβ)7,8. Although TGFβ has both anti-
and pro-proliferative roles; the current consensus is that
as tumours become aggressive, TGFβ signalling responses
are altered, resulting in the promotion of metastasis.
Indeed, treatment of multiple cell lines with TGFβ is
sufﬁcient to induce EMT9,10. Once they enter blood ves-
sels, cancer cells can bring about the aggregation of pla-
telets, triggering their activation and the release of
numerous small molecules and proteins, including TGFβ,
adenosine triphosphate (ATP), vascular endothelial
growth factor (VEGF) and platelet-derived growth factor
(PDGF)11,12. Platelets also protect cancer cells from
immune responses and shear stress, and they can alter
cancer cell behaviour, enabling extravasation and other
events important in metastasis13. Moreover, platelets are
also present in the tumour microenvironment as a result
of their extravasation14,15. Platelet-released signalling
molecules could therefore also induce or exacerbate EMT
in cancer cells as well as in pre-cancerous cells, and this
may also promote extravasation and metastasis.
The transcription factor PRH/HHEX (proline-rich
homeodomain/haematopoietically expressed homeobox)
is essential for the formation of many organs during
embryonic development16,17. PRH is expressed in many
tissues in the adult and downregulation of PRH protein
expression and/or aberrant subcellular localisation of
PRH is associated with breast, prostate, thyroid, and liver
tumours18. PRH inactivation is common to a number of
cancer types but the mechanisms of PRH inactivation vary
in different disease states. PRH mRNA levels are reduced
in breast cancer cells and in poorly differentiated hepa-
tocellular carcinomas19,20. In addition, PRH protein is
present in the nucleus and cytoplasm in normal breast
epithelial cells and normal thyroid tissues but in breast
and thyroid cancer cells, the protein is found pre-
dominantly in the cytoplasm20–22. Our recent studies have
shown that in prostate and breast cancer cells PRH is
inactivated by protein kinase CK2-dependent phosphor-
ylation of the PRH homeodomain23,24. Phosphorylation by
CK2 prevents PRH from binding to DNA and alters
nuclear retention. In addition, phosphorylation by CK2
targets PRH for processing by the proteasome creating a
truncated PRH phosphoprotein that is capable of acting as
a transdominant inhibitor of full-length transcriptionally
active PRH24.
Depletion of PRH in immortalised but otherwise
normal prostate PNT2-C2 epithelial cells and normal
immortalised breast MCF10A cells results in increased
cell migration and cell invasion25. In contrast, the
overexpression of PRH in prostate cancer PC3 cells and
breast cancer MCF-7 cells inhibits cell proliferation and cell
migration/invasion. Furthermore, PRH overexpression
inhibits extravasation by PC3 cells in an in vitro assay in
which cancer cells traverse a layer of conﬂuent endothelial
cells grown on Matrigel25. In addition, we showed recently
that PRH is inactivated in benign prostatic hyperplasia
(BPH) and prostate cancer cells via increased protein
phosphorylation26. This suggests that inactivation of PRH
could be important in the acquisition of a mesenchymal
phenotype during prostate tumourigenesis. Here, we show
that PNT2-C2 epithelial cells with depleted PRH are able to
traverse a layer of endothelial cells in an in vitro extra-
vasation assay. Importantly, the PRH-depleted cells are
more responsive to the stimulatory effects of blood platelets
in this assay than control cells. We show that TGFβ released
from platelets is responsible in part at least for the stimu-
lation of in vitro extravasation. Moreover, TGFβ induces
EMT-like changes in PNT2-C2 cells and prostate cancer
cells and this is accompanied by increased PRH phos-
phorylation and decreased PRH protein and mRNA levels.
These data indicate that TGFβ signalling inactivates PRH
using multiple mechanisms resulting in increased the sen-
sitivity to TGFβ signalling.
Results
PRH depletion increases in vitro extravasation
To determine whether depletion of PRH in prostate
epithelial cells enables extravasation, we made use of an
in vitro assay in which human umbilical vein endothelial
cells (HuVECs) are plated onto a layer of Matrigel in
transwell chambers and allowed to form a barrier (Fig.1a).
Each layer of HuVECs was tested to ensure that it was
impermeable to ﬂuorescein isothiocyanate (FITC)-label-
led dextran before use. Normal immortalised prostate
epithelial PNT2-C2 cells transfected with plasmids
expressing either a scrambled vector control (SVC)
shRNA or PRH shRNA and grown for 10 days in pur-
omycin selection were then plated onto the conﬂuent
HuVECs. After 48 h, the number of extravasated cell on
the lower side of the transwell ﬁlter was determined using
microscopy. Figure 1b shows that PRH knockdown (KD)
using shRNA resulted in a signiﬁcant increase in extra-
vasation in this assay. PRH levels in the control and PRH
KD cells are shown in Fig. 1c and demonstrate effective
KD.
Platelets stimulate in vitro extravasation
Blood platelets are known to stimulate extravasation of
cancer cells27,28. To examine the effects of platelets on
extravasation by PNT2-C2 cells and PNT2-C2 with
knocked down PRH, we pre-incubated cells with platelets
(1:1 ratio) for 24 h and then measured extravasation over a
further 24 h. Pre-incubation with platelets had little or no
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effect on the ability of control cells to traverse the endo-
thelial layer (Fig.1d). However, pre-incubation with pla-
telets resulted in a ﬁvefold increase in extravasation by the
PRH KD cells (Fig.1d). In these assays, the permeability of
the endothelial cell layer to FITC-labelled dextran was not
increased by exposure to platelets, suggesting that the
platelets act directly on the PRH KD cells. In keeping with
this conclusion the adherence of labelled platelets to
PNT2-C2 cells is increased following PRH KD (Fig.1e).
Taken together, these data suggest that endogenous PRH
is likely to repress invasion and extravasation of normal
cells and that loss of PRH activity in BPH and in prostate
cancer cells contributes to the acquisition of these abil-
ities. Experiments in breast cancer cells support this view
and indicate that this consequence of PRH inactivation is
not conﬁned to prostate cells: MCF-7 breast cancer cells
with knocked down PRH display increased extravasation
(Fig. S1). Moreover, pre-incubation with platelets results
in a signiﬁcant increase in extravasation (Fig. S1).
ATP and TGFβ signalling promote extravasation
Platelets release multiple growth factors and other sig-
nalling molecules that could stimulate extravasation by
PRH-depleted PNT2-C2 cells and MCF-7 cells29,30. We
ﬁrst tested whether ATP release by platelets is important
in the response of PNT2-C2 PRH KD cells. Treatment
with apyrase, an ATP diphosphohydrolase, reduced the
stimulatory effect of platelets on the PRH KD cells by >
50% (Fig. 2a), indicating that ATP signalling increases
extravasation by these cells. As our previous work has
shown that PRH directly regulates transcription of the
gene encoding the TGFβ co-receptor Endoglin25, we next
tested whether TGFβ signalling is important in this
context. We incubated PNT2-C2 PRH KD cells with
platelets in the presence and absence of SB431542, an
inhibitor of TGFβ signalling via the activin type I
receptors ALK5/4/731. Treatment with this inhibitor also
reduced the stimulatory effect of platelets on the PRH KD
cells by > 50% (Fig. 2a). To conﬁrm that platelets activate
Fig. 1 Blood platelets stimulate in vitro extravasation by immortalised prostate epithelial cells. a A schematic representation of an in vitro
extravasation assay. b PNT2-C2 cells expressing PRH shRNA (KD) or a scrambled vector control shRNA (SVC) were placed in a transwell chamber
containing a conﬂuent layer of HuVECs growing on Matrigel. After 48 h, the number of extravasated cells was determined by counting cells on the
lower side of the transwell ﬁlter using microscopy. Cells per ﬁeld, n= 3 independent experiments, mean and standard deviation (M+ SD), *p < 0.01.
c Western blot showing PRH protein levels in the cells from b with Lamin A/C as loading control. d The experiment shown in b was repeated with
SVC and PNT2-C2 PRH KD cells that had been pre-incubated with blood platelets (1:1 cells: platelets) for 24 h. M+ SD from three independent
experiments, *p < 0.01, ns= not signiﬁcant. e Platelet adhesion to control PNT2-C2 cells and PRH KD cells was measured using Calcein-labelled
platelets. Percentage platelet adhesion= (remaining ﬂuorescence−blank)/(total ﬂuorescence−blank) × 100. M+ SD, n= 3, *p < 0.01.
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the TGFβ signalling pathway in these cells and in prostate
cancer PC3 cells, we treated the cells with platelets and
examined the levels of pSMAD3, an effector of TGFβ
signalling. In both cell types, platelet treatment brings
about an increase in the levels of pSMAD3 (Fig. 2b). As
expected, treatment with platelets also increased cell
migration in both PNT2-C2 cells and PC3 cells (Fig. 2c).
We next treated PNT2-C2 cells with TGFβ and examined
pSMAD3 levels and cell migration. Treatment of these
cells with TGFβ increased pSMAD3 levels (Fig. 2d) and
increased cell migration by around fourfold (Fig. 2e). We
conclude that TGFβ and ATP released from platelets are
responsible, in part, at least for the effects of platelets on
PNT2-C2 cell migration and extravasation. As incubation
with platelets increased the migration of prostate cancer
PC3 cells, we also examined the effects of TGFβ on these
cells. As expected, treatment with TGFβ also increased
the migration of PC3 cells (Fig. 2e).
TGFβ induces EMT-like changes in PNT2-C2 cells
To examine the effects of TGFβ on PNT2-C2 cells in
more detail, we next examined cell morphology and the
expression of markers of EMT. We examined the mor-
phology of untreated and TGFβ-treated cells using
immunoﬂuorescence with antibodies that stain β-Actin
and 4′,6-diamidino-2-phenylindole (DAPI) to stain DNA.
Untreated PNT2-C2 cells are typically rounded and show
extensive cell–cell contacts characteristic of epithelial
cells (Fig. 3a). In contrast, TGFβ-treated PNT2-2C cells
display an elongated, spindle-shaped morphology typical
of mesenchymal cells (Fig. 3a). Western blotting reveals
that expression of the epithelial marker and cell adhesion
Fig. 2 ATP and TGFβ signalling increase prostate cell extravasation. a PNT2-C2 cells expressing PRH shRNA (KD) or a scrambled vector control
shRNA (SVC) were placed in a transwell chamber containing a conﬂuent layer of HuVECs growing on Matrigel. Cells were pre-treated with platelets as
in Fig. 1d in the absence and presence of apyrase treatment (columns 5 and 6) and in the absence and presence of 3 mM SB431542 (columns 5 and
7). After 24 h the number of extravasated cells was determined as described in Fig. 1b. Cells per ﬁeld, n= 3 independent experiments, M+ SD, *p <
0.01. b Immortalised prostate PNT2-C2 cells and prostate cancer PC3 cells were incubated with platelets (1:1) for 24 h. pSMAD3 levels were then
determined using western blotting with β-Actin as loading control. c Cell migration over 18 h was then examined using a transwell chemotaxis assay.
The percentage of cells migrated was determined by counting the cells on the top and bottom surfaces of the transwell ﬁlter using microscopy.
Three independent experiments, M+ SD, *p < 0.01. d PNT2-C2 cells were treated with 5 ng/ml TGFβ or vehicle for 48 h. Western blotting was then
used to measure pSMAD3 levels using Lamin A/C as loading control. e PNT2-C2 cells and prostate cancer PC3 cells were treated with 5 ng/ml TGFβ
for 48 h as above. Cell migration was then assayed as above. Three independent experiments, M+ SD, *p < 0.01.
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protein E-Cadherin is substantially reduced in the treated
cells (Fig. 3b) and quantitative PCR reveals that the CDH1
mRNA encoding E-Cadherin is signiﬁcantly reduced in
these cells (Fig. 3c). Expression of the mesenchymal
marker protein Snail is somewhat elevated in the TGFβ
treated cells (Fig. 3b). However, the SNAI1 mRNA
encoding this protein is upregulated by around ﬁvefold
(Fig. 3d). Interestingly, expression of the EMT end stage
marker Vimentin is not altered in the treated cells (Fig.
3b). As expected, pSMAD3 levels are upregulated in the
treated cells. We conclude that treatment with TGFβ
induces changes in PNT2-C2 cells that are generally
characteristic of EMT.
PC3 cells have a mesenchymal morphology and they
express very low levels of E-Cadherin, requiring long
exposures to visualise the protein in western blot
experiments. However, under these conditions western
blotting clearly reveals that E-Cadherin protein levels are
reduced following treatment with TGFβ (Fig. 3e). More-
over, the expression of Snail is increased in TGFβ-treated
cells (Fig. 3e) as are the levels of pSMAD3 (Fig. 3f).
However, as in the case of PNT2-C2 cells, Vimentin
expression is not altered in the treated cells (Fig. 3e). In
agreement with these results, quantitative PCR reveals
that the CDH1 mRNA is downregulated in the treated
cells (Fig. 3f), whereas the SNAI1 mRNA is upregulated
(Fig. 3g). Similar results were obtained using another
prostate cancer cell line (Fig. S2). Taken together, these
data indicate that TGFβ induces changes in gene
expression and cell behaviour in prostate cancer cells that
are similar to those induced in PNT2-C2 cells.
TGFβ increases PRH phosphorylation and decreases PRH
protein levels
The experiments described above highlight the impor-
tance of TGFβ in EMT in these cells. Our previous work
Fig. 3 TFGβ induces EMT-like changes in PNT2-C2 cells and PC3 cells. a–d Immortalised prostate PNT2-C2 cells were treated with 5 ng/ml TGFβ
for 48 h. Cell morphology was then assessed using immunoﬂuorescence to stain for β-Actin and DAPI to stain for DNA a. EMT markers (E-Cadherin,
Snail and Vimentin) and pSMAD3 levels were examined using western blotting with β-Actin and Lamin A/C as loading controls b. Following mRNA
extraction qRT-PCR was used to determine CDH1 and SNAI1 mRNA levels c and d, respectively. Three independent experiments with PCR reactions
performed in triplicate, M+ SD, *p < 0.01. e–g Prostate cancer PC3 cells were treated with 5 ng/ml TGFβ for 48 h as above. EMT markers and pSMAD3
levels were examined using western blotting as above e. qRT-PCR was used to determine CDH1 and SNAI1 mRNA levels as above (f and g,
respectively). *p < 0.01.
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showed that increased PRH phosphorylation is associated
with EMT-like changes in PNT2-C2 cells and that PRH
depletion results in increased cell migration and inva-
sion26. We therefore examined the effects of TGFβ and
platelets on PRH phosphorylation and PRH protein levels.
Western blotting reveals that treatment of PNT2-C2 cells
with TGFβ or platelets results in a reduction in PRH
protein levels (Fig. 4a, left and right panels, respectively).
Quantiﬁcation of multiple independent experiments
shows that TGFβ treatment brings ~ 50% reduction in
PRH protein levels in these cells (Fig. 4b, left). Moreover,
treatment with TGFβ or platelets also bring about
increases in PRH phosphorylation (Fig. 4a, lower panels).
Quantiﬁcation of multiple independent experiments
shows that TGFβ treatment brings about a twofold
increase in pPRH in these cells (Fig. 4b, right). These data
suggest that TGFβ treatment results in the inactivation of
PRH in these cells. To determine whether the increase in
PRH phosphorylation is dependent on protein kinase
CK2, we examined the effect of the CK2 inhibitor TBB on
TGFβ-induced PRH phosphorylation. Figure 4c shows
that in the absence of TBB treatment of PNT2-C2 cells
with TGFβ increases pPRH levels. However, in the pre-
sence of TBB TGFβ treatment fails to increase pPRH
levels (Fig. 4c). To determine whether TGFβ and platelets
induce similar changes in PRH levels and PRH activity in
prostate cancer cells, we next looked at the effects of these
treatments on PC3 cells. Both treatments bring about
reductions in PRH levels in PC3 cells and both treatments
increase the levels of pPRH (Fig. 4d).
TGFβ downregulates PRH mRNA levels and blocks the
upregulation of E-cadherin expression by PRH
SMAD proteins have been reported to regulate
expression of the PRH/HHEX gene in the mouse
embryo32. To determine whether TGFβ regulates PRH
gene expression, we treated PNT2-C2 cells with TGFβ
and examined PRHmRNA levels using qRT-PCR. Figure 5a
shows that treatment of these cells with TGFβ results in a
signiﬁcant reduction in PRH mRNA relative to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA levels (Fig. 5a, left panel). Similarly, treatment of
prostate cancer PC3 cells with TGFβ results in a decrease
in PRH mRNA (Fig. 5a, right panel). To examine whether
Fig. 4 TGFβ increases PRH phosphorylation and downregulates PRH protein levels. a PNT2-C2 cells were treated with either 5 ng/ml TGFβ or
platelets (1:1) or vehicle for 48 h. Western blotting was then used to examine PRH and pPRH levels using Lamin A/C as a loading control. b Three
independent experiments performed as in a were quantiﬁed using densitometry. M+ SD, *p < 0.01. c Left. PNT2-C2 cells were treated with 5 ng/ml
TGFβ in the presence of absence of the Protein Kinase CK2 inhibitor TBB (10 μM) 48 h. Western blotting was then used to examine pPRH levels using
Lamin A/C as a loading control. Right. Three independent experiments were quantiﬁed using densitometry. M+ SD, *p < 0.01. d The experiment
shown in part a was repeated using prostate cancer PC3 cells.
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this change in gene expression correlates with changes in
the binding of SMAD proteins at the PRH gene we made
use of chromatin immunoprecipitation (ChIP) assays. PC3
cells were treated with TGFβ before ﬁxation and ChIP
using a pSMAD3 antibody or IgG as a negative control.
Quantitative PCR was then used to determine whether
PRH promoter sequences are preferentially pulled down.
Following TGFβ treatment there is a statistically sig-
niﬁcant increase in enrichment in PRH promoter
sequences (Fig. 5b) indicating that binding of pSMAD3 is
increase under these conditions. In contrast, sequences
from a gene desert region of chromosome 18 did not
show any enrichment following TGFβ treatment (Fig. 5b).
As TGFβ treatment results in decreased PRH mRNA
levels and decreased PRH protein levels, and since this
correlates with increased binding of pSMAD3 to the PRH
promoter, we next tested whether overexpression of PRH
from a heterologous promoter could negate the effects of
TGFβ on prostate cells. We overexpressed Myc-tagged
PRH in PC3 cells under the control of the CMV promoter
using a recombinant adenovirus (Ad-PRH) and then
treated the cells with TGFβ. Consistent with our previous
studies, overexpression of PRH resulted in increased
expression of E-Cadherin (Fig. 5c). However, treatment of
the PRH-overexpressing cells with TGFβ abrogated the
effects of PRH on E-Cadherin protein levels (Fig. 5c,
rightmost lane). These data show that the overexpression
of PRH is insufﬁcient to block the effects of TGFβ on
these cells.
PRH regulates multiple genes involved in EMT and TGFβ
signalling
Our previous work showed that PRH regulates the
transcription of Endoglin, a TGFβ co-receptor that
modulates TGFβ signalling25. Similarly, we have shown
that PRH regulates the transcription of E-Cadherin26.
This raises the question of whether PRH regulates other
genes involved in TGFβ signalling and EMT. To investi-
gate this we took an unbiased genome wide approach
using microarrays. We overexpressed Myc-PRH in PNT2-
C2 cells using a recombinant adenovirus as described
above and used empty adenovirus as a control. We
extracted mRNA from three independent experiments
and three independent control infections and performed
microarray experiments. In total, 6094 genes were sig-
niﬁcantly upregulated and 2373 genes downregulated
between PRH-overexpressing cells and the control cells
(fold change > 1.5). Gene ontology was then performed
using gene set enrichment analysis (GSEA, for genes with
false discovery rate (FDR) adjusted p < 0.1) using
the Hallmark gene sets. Figure 6a shows signiﬁcantly
enriched gene sets. The gene set with the most signiﬁcant
alteration contains genes involved in EMT including
VEGFC (x0.24), MMP3 (x0.45), and BMP1 (x1.7). Other
Fig. 5 TGFβ downregulates PRH mRNA levels and prevents the
activation of E-cadherin expression by PRH. a PNT2-C2 cells and
PC3 cells were treated with 5 ng/ml TGFβ for 48 h. qRT-PCR was the
used to determine PRH mRNA levels relative to GAPDH mRNA. The
data shown are from three independent experiments each performed
with triplicate PCR reactions. M+ SD, *p < 0.01. b PC3 cells were
infected with Ad-GFP or Ad-PRH at MOI 100 for 24 h then treated with
5 ng/ml TGFβ for a further 48 h. Chromatin immunoprecipitation was
then performed using IgG or pSMAD3 antibodies followed by
quantitative PCR using HHEX primers and Chromosome 18 gene
desert primers as negative control. The results shown are from three
independent experiments performed with triplicate PCR reactions.
M+ SD, *p < 0.01. c PC3 cells were infected with Ad-ΔE1 empty virus
or Ad-PRH at MOI 100 for 24 h. The cells were then treated with
vehicle (V), 5 ng/ml TGFβ (T), or control for 48 h. Western blotting was
then performed for Myc-PRH and E-Cadherin with Lamin A/C and
β-Actin as loading controls, respectively.
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signiﬁcantly altered gene sets contain genes involved in
oestrogen responses and the p53 pathway. Interestingly,
TGFβ response genes also showed signiﬁcant alteration
including Endoglin (x1.6), SMAD6 (x1.8), and Noggin
(x3.1). We validated these results using qRT-PCR to
examine the expression of Endoglin mRNA (Fig. 6a,
inset). To determine whether PRH overexpression would
also alter the expression of TGFβ response genes in
prostate cancer cells we infected PC3 cells with Ad-PRH
or Ad-empty and we examined the expression of selected
genes using qRT-PCR (Fig. 6b). As expected, PRH mRNA
(HHEX) and CDH1 mRNA levels are increased following
PRH overexpression. PRH mRNA levels are modestly
increased at this multiplicity of infection (MOI). Inter-
estingly, this modest overexpression results in a sig-
niﬁcant repression of TGFB2 and TGFBR2 mRNA levels.
We conclude that PRH regulates the expression of mul-
tiple genes involved in EMT and TGFβ signalling in
normal prostate cells and in prostate cancer cells.
Discussion
Tumour cells are exposed to TGFβ from multiple
sources both at their site of origin and during their
metastasis to secondary sites. Prostate tumourigenesis is
associated with inﬂammation, and immune cells produce a
variety of signalling molecules that increase prostate can-
cer risk and aggressiveness including TGFβ6. Platelets are
important in inﬂammation and in multiple disease states,
and an elevated blood platelet count is indicative of a poor
prognosis in breast cancer and other malignancies30,33.
Several studies indicate that this is due in part at least to
increased metastasis. For example, treatment of mouse
colon carcinoma cells or mammary carcinoma cells with
platelets prior to tail-vein injection increased the number
of lung metastases and induced EMT-like changes in the
treated cells34. The platelet-treated cells formed fewer
metastases in mice lacking TGFβ in platelets and mega-
karyocytes than in wild-type mice, suggesting that platelet-
derived TGFβ is important for the increased metastatic
potential of these cells34. In addition, platelet-released
ATP binds to P2Y2 receptors on blood vessel endothelial
cells, inducing opening of the endothelial barrier and
aiding, or allowing, the passage of cancer cell27. However,
as well as activating P2Y2 receptors on endothelial cells,
platelet-released nucleotides activate platelet P2Y12
receptors and this autocrine loop is known to enhance
platelet aggregation and the release of TGFβ from
platelet alpha granules28. TGFβ also induces opening of
the endothelial barrier in this case by disrupting endo-
thelial cell–cell junctions35.
The PRH protein regulates the proliferation of prostate
epithelial cells and inhibits cell migration and inva-
sion25,26. However, PRH phosphorylation inhibits PRH
function and in BPH increased PRH phosphorylation
correlates with increased cell proliferation26. In prostate
cancer cells, PRH is also hyperphosphorylated26. More-
over, in these cells, PRH mRNA expression is reduced and
in ~ 4% of prostate cancer patients the PRH gene is
deleted. We have shown previously that experimental
depletion of PRH in normal immortalised prostate
Fig. 6 Differentially expressed gene sets in PNT2-C2 cells overexpressing PRH. a PNT2-C2 cells were infected with Ad-GFP or Ad-PRH at MOI 50
as in Fig. 5b. Changes in gene expression were then detected using microarrays and differentially expressed genes identiﬁed using SAM (statistical
analysis of microarray, false discovery rate adjusted p < 0.01). Inset: relative expression of the TGFβ co-receptor Endoglin mRNA in the Ad-empty and
Ad-PRH infected PNT2-C2 from cells from part A were determined by qRT-PCR and normalised to β-Actin mRNA (M+ SD, n= 3, *p < 0.05). b PC3
cells were infected with Ad-empty and Ad-PRH as above and after 24 h mRNA levels were determined by qRT-PCR and normalised to GAPDH mRNA
(M+ SD, n= 3 independent experiments with triplicate PCR reactions, *p < 0.05).
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epithelial cells induces EMT-like changes including
increased cell migration and invasion and reduced
expression of E-Cadherin26. In contrast, overexpression of
PRH in prostate cancer cells inhibits proliferation and
blocks cell migration and cell invasion25. We show that
depletion of PRH in normal immortalised prostate epi-
thelial cells increases platelet adhesion and increases the
sensitivity of these cells to the stimulatory effects of pla-
telets in an in vitro extravasation in which they must
traverse a layer of endothelial cells and invade Matrigel.
This suggests that the downregulation of PRH in BPH and
in prostate cancer cells contributes to the acquisition of
an invasive phenotype. The stimulatory effects of platelets
on the extravasation of PRH-depleted cells is signiﬁcantly
reduced following treatment with an ATP dipho-
sphohydrolase, indicating that ATP signalling is impor-
tant in this process. The effects of platelets in this assay
are also largely abrogated following the inhibition of
TGFβ signalling. Moreover, TGFβ treatment increases the
migratory potential of these cells and has similar effects
on prostate cancer cells. These phenotypic changes are
accompanied by the downregulation of E-Cadherin pro-
tein levels and the upregulation of Snail expression,
changes that are indicative of the loss of epithelial char-
acteristics and the gain of mesenchymal characteristics.
The mechanisms that enable TGFβ to induce EMT have
been studied in some detail. However, here we show that
TGFβ treatment increases PRH phosphorylation in nor-
mal immortalised prostate cells and prostate cancer cells.
TGFβ treatment also downregulates PRH mRNA levels
and PRH protein levels in these cells. Both of these
mechanisms are likely to contribute to the induction of
EMT and to be of relevance in prostate cancer progres-
sion. As PRH appears to function as a tumour suppressor
in breast cancer cells and some other cancer cells18, it is
likely that some or all of these mechanisms are important
in the context of these diseases.
We have shown that PRH regulates the expression of
multiple genes involved in EMT and TGFβ signalling in
prostate cells. Thus, the downregulation of PRH activity
by TGFβ has consequences for the expression of these
genes and for the induction of EMT. We propose that the
downregulation of PRH activity by TGFβ shapes the
response of normal prostate cells and prostate cancer cells
to immune signalling in the prostate and inﬂuences the
response of cancer cells to these signals during metastasis.
Moreover, changes in PRH activity will inﬂuence signal-
ling from normal prostate cells and prostate cancer cells
to immune cells. This feedback loop is likely to be
important in cancer progression, and it represents a novel
target for drug discovery and drug development. Drugs
that prevent PRH phosphorylation such as the protein
kinase inhibitor CX4945, for example, would be expected
to downregulate some of the effects of TGFβ on these
cells. Our future studies will address this question and the
wider role of PRH-TGFβ co-regulation in other
tumour types.
Materials and methods
Cell culture
PNT2-C2 cells were a kind gift from Professor Norman
Maitland (University of York). PC3 cells and MCF-7 cells
were obtained from ATCC. PNT2-C2 cells, PC3 cells,
and MCF-7 cells were cultured in Roswell Park Memorial
Institute (RPMI)-1640 medium (Sigma-Aldrich) supple-
mented with 10% fetal bovine serum (FBS), 2 mM
L-glutamine, and 1% penicillin/streptomycin. HuVECs
(PromoCell) were cultured in DMEM: F12 supplemented
with 5 ng/ml epidermal growth factor, 10 ng/ml basic
ﬁbroblast growth factor, 20 mg/ml heparin, 1 mg/ml
hydrocortisone, 250 ng/ml insulin, 1% penicillin/strepto-
mycin, and 2% fetal calf serum. Cells were maintained in a
humidiﬁed atmosphere at 37 °C and 5% CO2.
PRH KD and overexpression
PRH expression was knocked down in PNT2-C2 cells
by transfecting 5 × 106 cells with 5 µg PRH49 and 5 µg
PRH51 shRNA plasmids (Origene) using TransIT pros-
tate transfection reagent (Mirus, Madison, WI, USA).
Cells transfected with 10 µg SVC shRNA were used as a
control. Cells were selected in media containing 1 µg/ml
puromycin added 24 h post transfection and experiments
were performed using cells harvested at day 10. PRH
expression was knocked down in MCF-7 cells using an
isopropyl b-D-1-thiogalactopyranoside-(IPTG) inducible
PRH shRNA lentiviral construct (TRCN0000274008
Sigma-Aldrich) as described25. Cells transduced with the
PRH shRNA virus or control scrambled shRNA virus
were selected using puromycin and grown in the presence
of 1 mM IPTG for 7 days to induce shRNA expression.
PRH was overexpressed using an Adenoviral-Myc-PRH
(Ad-PRH) construct36 at a MOI of 1: 100 for 24 h at 37 °C
and 5% CO2. An adenovirus expressing β-galactosidase
(Ad-β-gal) and empty virus were used as negative
controls.
Whole-cell extracts and western blotting
Western blotting was performed as described pre-
viously37 except that cells were lysed in lysis buffer (Cell
Signalling) containing 1 µM phenylmethylsulfonyl ﬂuoride
and 1× PhoStop (Roche) with sonication on ice water for
10minutes. Antibodies are listed in Table 1.
Platelet preparation and adhesion assays
Platelets were prepared from freshly taken human blood
as described previously38. Human blood was obtained
from healthy drug-free volunteers, who gave full informed
consent in accordance with the Declaration of Helsinki,
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and with approval from the local research ethics com-
mittee of the University of Bristol. For platelet adhesion
assays, PNT2-C2 SVC control cell and PRH KD cells (1 ×
105 cells per well) were seeded in a tissue-culture treated
96-well plate (Corning), and incubated at 37 °C for 2 h.
Platelets preloaded with 4 µM, Calcein-AM (Sigma-
Aldrich) were then added and allowed to adhere to the
cells for 45 min at 37 °C. Total ﬂuorescence per well was
measured using a microplate reader (Molecular Devices)
at 485 nm. After three washes with phosphate-buffered
saline (PBS), 100 µl of PBS was added to each well and the
remaining ﬂuorescence was read as above. Percentage
platelet adhesion was calculated as: (remaining ﬂuores-
cence−blank)/(total ﬂuorescence−blank) × 100.
Cell migration, invasion, and extravasation assays
Cell migration, cell invasion, and cell extravasation
assays were performed as described previously25. In brief,
chemotaxis assays were performed by seeding cells into
Boyden chambers (Greiner Bio-One) in RPMI medium
with 2% FBS in 24-well plates containing 800 µl RPMI with
10% FBS. The cells were ﬁxed with 4% paraformaldehyde
(Fisher) and stained with 2 µg/ml bisbenzimide (Sigma-
Aldrich) before counting cells on the top and bottom of
the ﬁlter using a Leica Q550 inverted epiﬂuorescence
microscope. Alternatively, migrated cells were incubated
with RPMI containing 8 µM Calcein-AM for 45minutes
then removed using trypsin-ethylenediaminetetraacetic
acid (EDTA) (37 °C) and placed in a black ﬂat bottom
96-well plate and read using a ﬂuorescent plate reader at
an excitation wavelength of 485 nm and an emission
wavelength of 520 nm. For invasion assays, 50% Matrigel
(BD Biosciences) was added to each chamber and solidi-
ﬁed at 37 °C for 1 h before seeding cells. Extravasation
assays were performed after seeding HuVECs onto
Matrigel and testing permeability to FITC-labelled dextran
(Sigma-Aldrich). In some experiments cells were incu-
bated with platelets in a 1:1 ratio before plating onto
conﬂuent HuVECs. SB431542 and apyrase were purchased
from Sigma-Aldrich.
Immunoﬂuorescence microscopy
Cells were seeded onto 22mm2 cover slips (Fisher) in
six-well plates and left overnight to adhere. The cells were
then ﬁxed and permeabilised for immunoﬂuorescent
staining as described previously39. After mounting with
VectaShield medium containing DAPI (Vector Labs),
imaging was carried out using a Leica Q550 inverted
epiﬂuorescence microscope with DAPI, GFP, and TRITC
ﬁlter sets.
ChIP
ChIP was performed as described previously with minor
modiﬁcations25. After ﬁxation, cells were resuspended in
10mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES), pH 8.0; 10mM EDTA; 0.5mM EGTA; 0.25 %
Triton X-100; 1 µM PFSM and 1 × PhoStop and incubated
on rocker for 10min at 4 °C. Following centrifugation for
5min at 500 × g, 4 °C the pellet was resuspended in 10mM
HEPES, pH 8.0; 200mM NaCl; 1 mM EDTA; 0.5mM
EGTA; 0.01 % Triton X-100; 1 µM PFSM and 1 × PhoStop
and incubated at 4 °C for 10minutes. After recentrifuga-
tion, the pellet was resuspended in 1ml ChIP buffer
(25mM Tris-HCl, pH 8.0; 150mM NaCl; 2 mM EDTA; 1 %
Triton X-100; 0.25 % SDS; 1 µM PFSM and PhoStop) and
disrupted using a Vibra cell sonicator with a micro tip.
Chromatin–antibody complexes were precipitated using
Dynabeads-Protein G (Invitrogen) at 4 °C for 4 h. The
DNA was ﬁnally puriﬁed using AXYPREP magnetic PCR
clean-up (Axygen Scientiﬁc).
Table 1 Antibodies used in this study.
Antibody Species Source Dilution
anti-Hex mAb, clone 4B7 Mouse OriGene Technologies 1:1000
pPRH (YKN5) polyclonal Rabbit In house 1:2500
Phospho-Smad3 (Ser423/425) (C25A9) Rabbit mAb 9520 Rabbit Cell Signalling Technology 1:1000
E-Cadherin (24E10) mAb 3195 Rabbit Cell Signalling Technology 1:1000
β-Actin (D6A8) mAb 8457 Rabbit Cell Signalling Technology 1:1000
Snail (C15D3) mAb 3879 Rabbit Cell Signalling Technology 1:1000
Lamin A/C mAb 2032 Rabbit Cell Signalling Technology 1:1000
Myc-Tag (9B11) mAb 2276 Mouse Cell Signalling Technology 1:1000
Anti-mouse IgG, HRP conjugate AP160P Rabbit Sigma-Aldrich 1:5000
Anti-rabbit IgG, HRP conjugate 12–348 Goat Sigma-Aldrich 1:5000
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Quantitative PCR
Primers are listed in Table 2. mRNA extraction and RT-
qPCR was performed as described previously25,37 in tri-
plicate for the gene of interest with GAPDH as an internal
control. Data was analysed using Rotorgene 6 software
(Corbett Research; Rotorgene RG-3000) and fold change
in expression determined using the efﬁciency adjusted
quantitative PCR method40. For quantitative ChIP, PCR
was performed in quadruplicate using 2× Rotor-Gene
SYBR Green PCR Master Mix and the results expressed as
percentage of input recovered.
Microarrays
PNT2-C2 cells were infected with Ad-PRH or Ad-β-gal
as a negative control as above. After 24 h mRNA was
extracted using an RNeasy mini kit (Qiagen) and used for
double-stranded cDNA synthesis (Roche). After labelling
with Cy3 (NimbleGen One-Colour DNA labelling kit) the
cDNA was hybridised to a Roche NimbleGen 12 × 135 K
gene expression microarray. The array was then washed
and scanned using the MS 200 Microarray Scanner. Data
from three independent experiments were extracted and
normalised by robust multi-array analysis using DEVA
software (v1.2.1). Statistical analysis of microarray analysis
using MeV software (v4.9) was used to identify genes
showing signiﬁcantly altered expression. Gene lists were
generated using fold change < 1.5 and FDR adjusted p
values of < 0.1. Gene ontology was assessed using
GSEA41,42.
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